表 2　基本解析結果

	Costs (Yen per hospital)	
Strategy	Annual costs	Annual costs saved
Hospital with infection control team	4,539,887843	212,026,460
Hospital without infection control team	4,751,914,303	

表 3　1 次元感受性分析結果

Variables	Saved Costs for Hospital with Infection Control Team
Incidence of nosocomial infection	113,355,365-311,037,801
Hazard rate ratio of infectin control team	-19,000,000-262,563,499
Length of hospital stay	
Patients without nosocomial infection	150,466,388-273,586,533
Patients with nosocomial infection	99,166,327-330,016,600
In-hospital mortality	
Patients without nosocomial infection	209,250,787-214,802,134
Patients with nosocomial infection	202,535,446-221,472,706
Costs	
Hospitalization daily costs	109,429,908-314,630,150
Nosocomial infection treatment costs	206,903,235-217,149,864
Cost related to death	204,236,697-219,816,286
Employment of one infection control doctor	205,526,460-218,526,460
Employment of one infection control nurse	209,026,460-215,026,460
Simulation hospital	
Number of beds	188,923,814-235,129,107
Bed utilization rate	186,356,854-237,696,067

図 1　決断分岐樹


Hospital
No ICT
ICT
Nosocomial infection
p_NI
No nosocomial infection
#
Nosocomial infection
r_ICT*p_NI
No nosocomial infection
#
Death with nosocomial infection
m_NI
Discharge after extended hospital stay
#
Death without nosocomial infection
m_noNI
Discharge after regular hospital stay
#
Death with nosocomial infection
m_NI
Discharge after extended hospital stay
#
Death without nosocomial infection
m_noNI
Discharge after regular hospital stay
#

図２　１次元感受性分析（ハザード比）



図３　２次元感受性分析（ハザード比および
院内感染発生率）



図4　モンテカルロシミュレーション



感染症流行の周期性

国立国際医療センター研究所　　尾又一実、山本健二、新保卓郎

Periodicity of the Epidemic of Infectious Diseases

International Medical Center of Japan
Kazumi Omata, Kenji Yamamoto and Takuro Shimbo

感染症に対するワクチン接種効果と、接種開始後の感染症発生率の周期性を調べるために、Kermack-McKendrick 型のモデルに基づく理論的研究を行った。具体的な感染症として風疹を取上げ、先天性風疹症候群 (CRS: Congenital Rubella Syndrome) の発生率の時間変化を調べた。計算された発生率に対してモード解析を行うと、周波数の大きな振動モード (モード I) と緩やかな減衰モード (モード II) があることがわかる。２つのモードのパワースペクトル強度を、ワクチン接種年齢 b と出生率 x_0 で張られる２次元空間上に等高線で示したものが下図である。この図から、モード I は b が小さい領域で、モード II は b が大きい領域でスペクトル強度が大きくなることがわかる。また、$x_0 < 2000$ の領域は両モード共にスペクトル強度が小さいが、これはワクチン接種の効果が小さいこと意味しているのではなく、ＣＲＳの発生率が急激に減少するため、パワースペクトルの中に現れなくなることを示している。



図：モード I (左図) とモード II (右図) に対するパワースペクトル強度の等高線。

院内感染対策の有効性および費用効果に関する研究

研究成果の刊行に関する一覧表

雑誌

Takahashi O, Shimbo T, Rahman M, Kurokawa W, Yoshinaka T, Fukui T. Validation of Auscultatory Method for Diagnosing Peripheral Arterial Disease. *Fam Pract.* 2006 Feb;23(1):10-4.

Takahashi O, Shimbo T, Rahman M, Okamoto S, Tanaka Y, Fukui T. Evaluation of cuff-wrapping methods for the determination of ankle blood pressure. *Blood Press Monit.* 2006 Feb;11(1):21-6.

Miura Y, Asai A, Matsushima M, Nagata S, Onishi M, Shimbo T, Hosoya T, Fukuhara S. Families' and physicians' predictions of dialysis patients' preferences regarding life-sustaining treatments in Japan. *Am J Kidney Dis.* 2006 Jan;47(1):122-30.

Nagata-Kobayashi S, Sekimoto M, Koyama H, Yamamoto W, Goto E, Fukushima O, Ino T, Shimada T, Shimbo T, Asai A, Koizumi S, Fukui T. Medical Student Abuse During Clinical Clerkships in Japan. *J Gen Intern Med.* 2006;21:212-218.

Fukui T, Rahman M, Shimbo T, Morita S, Sakamoto J. Recruitment of patients for a clinical trial: factors on the physician side and reasons on the patient side. *Intern Med.* 2006;45(8):511-4.

Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. *Int J Cardiol.* 104: 213-23; 2005.

Maeda K, Shimbo T, Fukui T. Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan. *Journal of Medical Screening* 2004;11(2):97-102

Fukui T, Rhaman M, Takahashi O, Saito M, Shimbo T, Endo H, Misao H, Fukuhara S, Hinohara S. The ecology of medical care in Japan. *Japan Medical Association Journal* 48:163-167, 2005

Satomura K, Kitamura T, Kawamura T, Shimbo T, Watanabe M, Kamei M, Takano Y, Tamakoshi A; for the Great Cold Investigators. Water gargling prevents upper respiratory tract infections: a randomized controlled trial. *Am J Prev Med* 2005;29:302-7.

Suzuki H, Fukushima M, Okamoto S, Takahashi O, Shimbo T, Kurose T, Yamada Y, Inagaki N, Seino Y, Fukui T. Effects of thorough mastication on postprandial plasma glucose concentrations in nonobese Japanese subjects. *Metabolism.* 2005 Dec;54(12):1593-9.

Morimoto T, Oguma Y, Yamazaki S, Sokejima S, Nakayama T, Fukuhara S. Gender differences in effects of physical activity on quality of life and resource utilization. *Qual Life Res* 2006;15:537-46.

Nakamura T, Takahashi O, Matsui K, Shimizu S, Setoyama M, Nakagawa M, Fukui T, Morimoto T. Clinical prediction rules for bacteremia and in-hospital death based on clinical data at the time of blood withdrawal for culture: an evaluation of their development and use. *J Eval Clin Pract* 2006 (in press).

Nomura K, Kawasugi K, Morimoto T. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. *Eur J Cancer Care* 2006;15:44-50.

Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K. Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease. *Osteoporos Int* 2006 (in press)

Kanatsu-Shinohara M, Inoue K, Miki H, Ogonuki N, Takehashi M, Morimoto T, Ogura A, Shinohara T. Clonal origin of germ cell colonies after spermatogonial transplantation in mice. *Biol Reprod* 2006 (in press)

Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. *J Bone Miner Metab* 2006;24:105-13.

Taji Y, Morimoto T, Fukuhara S, Fukui T, Kuwahara T. Effects of low dialysate calcium concentration on health-related quality of life in hemodialysis patients. *Clin Exp Nephrol* 2005;9:153-7.

Okamoto S, Kamiya I, Kishida K, Shimakawa T, Fukui T, Morimoto T. Experience with oseltamivir for infants younger than 1 year old in Japan. *Pediatr Infect Dis J* 2005;24:575-576.

Nomura K, Nakao M, Morimoto T. Effects of smoking on hearing loss: Quality assessment and meta-analysis. *Prev Med* 2005;40:138-44.

Kosuge M, Kimura K, Kojima S, Sakamoto T, Matsui K, Ishihara M, Asada Y, Tei C, Miyazaki S, Sonoda M, Tsuchihashi K, Yamagishi M, Ikeda Y, Shirai M, Hiraoka H, Inoue T, Saito F, Ogawa H; on behalf of the Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Effects of glucose abnormalities on in-hospital outcome after coronary intervention for acute myocardial infarction. *Circ J* 69: 375-379; 2005.

Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M, Tei C, Hiraoka H, Sonoda M, Tsuchihashi K, Shimoyama N, Honda T, Ogata Y, Matsui K, Ogawa H, on behalf of the Japanese Acute Coronary Syndrome Study (JACSS) Investigators . Prognostic Usefulness of Serum Uric Acid After Acute Myocardial Infarction (The Japanese Acute Coronary Syndrome Study) *Am J Cardiol* 96: 489 - 485; 2005.

Kudoh T, Sakamoto T, Miyamoto S, Matsui K, Kojima S, Sugiyama S, Yoshimura M, Ozaki Y, Ogawa H. Relation between platelet microaggregates and ankle brachial index in patients with peripheral arterial disease. *Thromb Res.* 117:263-9; 2006.

Aoki T, Takahashi JA, Ueba T, Oya N, Hiraoka M, Matsui K, Fukui T, Nakashima

Y, Ishikawa M, Hashimoto N. Phase II study of Vincristine, Nimustine, Carboplatin and Interferon-beta With Radiotherapy for Glioblastoma : Kyoto Neuro-Oncology Group. *J Neurosurg* (in press).

Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Matsui K, Sakamoto T, Yoshimura M, Kimura K, Umemura S, Ogawa H. Plasma Adiponectin Levels are Associated with Coronary Lesion Complexity in Men with Coronary Artery Disease. J Am Coll Cardiol. (in press)

小林志津子、斉藤繭子、片岡明美、大野真司、中村清吾、福井次矢、小山弘、新保卓郎. 日本人女性の乳癌検診受診行動の促進要因と阻害要因の検討. *日乳癌検診学会誌*. 2006 15(1):69-74

新保卓郎. 診療ガイドラインとEBM. *臨床薬理* 37 : 15-20, 2006

新保卓郎. 抗生物質、合成抗菌薬の効果はあるか？ *EBM ジャーナル* 6 : 20-24, 2005

大西丈二、新保卓郎. 臨床疫学の基礎知識. *Diabetes Frontier* 16:89-94;2005

新保卓郎. 医療と宗教　祈りと援助. *JIM* 15;510-512,2005

須藤章、小田垣孝雄、新保卓郎、小山弘. 膵から汁. *JIM* 15;635-637,2005

Journal of Evaluation in Clinical Practice, 11, ∞, ∞–∞

Clinical prediction rules for bacteremia and in-hospital death based on clinical data at the time of blood withdrawal for culture: an evaluation of their development and use

Tsukasa Nakamura MD (Research Fellow),[1,2] Osamu Takahashi MD (Research Fellow),[1] Kunihiko Matsui MD MPH (Assistant Professor),[3] Shiro Shimizu MD (Vice President),[2] Motoichi Setoyama MD (President),[4] Masahisa Nakagawa MD (President),[5] Tsuguya Fukui MD MPH (President)[6] and Takeshi Morimoto MD MPH (Instructor)[1]

[1]Department of General Medicine and Clinical Epidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
[2]Department of General Medicine, Shimane Prefectural Central Hospital, Izumo, Japan
[3]Comprehensive Clinical Education, Training, and Development Center, Kumamoto University Hospital, Kumamoto, Japan
[4]Kochi Health Sciences Center, Kochi, Japan
[5]Shimane Prefectural Central Hospital, Izumo, Japan
[6]St. Luke's International Hospital, Tokyo, Japan

Correspondence
Takeshi Morimoto
Division of General Internal Medicine
Kyoto University Hospital
54 Kawahara-cho
Shogoin
Sakyo-ku
Kyoto 606-8507
Japan
E-mail: morimoto@kuhp.kyoto-u.ac.jp

Keywords: bacteremia, blood cultures, clinical prediction rules, gram-negative bacteria, integrated intelligent management system, mortality

Accepted for publication:
9 May 2005

Abstract

Rationale, aims and objectives To develop clinical prediction rules for true bacteremia, blood culture positive for gram-negative rods, and in-hospital death using the data at the time of blood withdrawal for culture. **Methods** Data on all hospitalized adults who underwent blood cultures at a tertiary care hospital in Japan were collected from an integrated medical computing system. Logistic regression was used for developing prediction rules followed by the jackknife cross validation. **Results** Among 739 patients, 144 (19.5%) developed true bacteremia, 66 (8.9) were positive for gram-negative rods, and 203 (27.5%) died during hospitalization. Prediction rule based on the data at the time of blood withdrawal for culture stratified them into five groups with probabilities of true bacteremia 6.5, 9.6, 21.9, 30.1, and 59.6%. For blood culture positive for gram-negative rods, the probabilities were 0.6, 4.7, 8.6, and 31.7%, and for in-hospital death, those were 6.7, 15.5, 26.0, 35.5, and 56.1%. The area of receiver operating characteristic for true bacteremia, blood culture positive for gram-negative rods, and in-hospital death were 0.73, 0.64, and 0.64, respectively, in original cohort and 0.72, 0.64, and 0.64 in validation respectively. **Conclusions** The clinical prediction rules are helpful for improved clinical decision making for bacteremia patients.

Introduction

Bacteremia is a serious condition with a high mortality from 11 to 69% (Watanakunakorn & Weber 1989; Arpi *et al.* 1995; Rangel-Frausto *et al.* 1995; Martin *et al.* 2003), and therefore needs prompt and careful management involving the proper use of the antibiotics. However, it usually takes several days to receive results of blood cultures, and as many as 66% of blood cultures are reported to be contaminated (Bates *et al.* 1997). If doctors can accurately estimate the probability of bacteremia, the type of microorganism, and mortality when conducting blood cultures, they can decide the starting and type of antibiotics more rationally and thus reduce inappropriate antibiotics usage.

Several reports have dealt with the risk factors for bacteremia (Bone 1987; Leibovici *et al.* 1990) and clinical prediction rules were formatted for true bacteremia or sepsis using reported blood culture results at hand and other clinical data (Mellors *et al.* 1987; Bates & Lee 1992; Bates *et al.* 1997). However, there are few reports concerning clinical prediction rules for true bacteremia and mortality at once based not on reported blood culture results but on clinical data at the time of blood culture. We therefore conducted a retrospective cohort study to develop clinical prediction rules for (1) true bacteremia; (2) positivity of gram-negative rods; and (3) in-hospital death based on clinical data at the time of blood culture.

Methods

Patient population

Data collection took place in all wards and intensive care unit at Shimane Prefectural Central Hospital, a tertiary care hospital in Japan. This hospital features an Integrated Intelligent Management System, a medical computing system consisting of electronic medical records, nursing logs, doctor's orders, laboratory and imaging results, prescription data, and hospital claims. Subject patients were all adults at the age of 18 or more who underwent blood cultures between August 1999 and December 2002. We took into account the first blood culture for one patient because the likelihood of true bacteremia was strongly suggested by the previous blood culture results.

This study was approved by the Institutional Review Board of Shimane Prefectural Central Hospital, and the informed consent was waived because it was conducted in historical cohort fashion without any intervention and the individual identification information was not used.

Definition of true bacteremia

We considered blood culture results as 'true bacteremia' (1) if the cultured organism was a gram-negative rod, fungus, or anaerobic; (2) if the same organism was cultured more than twice; (3) if the same organism was cultured from such specimens as urine, sputum, catheter or operative sample; and (4) endocarditis was present clinically or at autopsy. All cases were carefully reviewed independently by two internists (TN and OT) and classified as positive when both of them judged true bacteremia, otherwise considered contamination (false-positive). The kappa score of agreement between the reviewers was 0.78 (95% confidence interval: 0.69–0.86).

Data collection

One investigator (TN) identify the patients who underwent blood culture during the study period from the Integrated Intelligent Management System. Clinical data retrieved were age, gender, days from the admission to blood culture, major co-morbidities (coma, brain death, bowel perforation, multiple trauma, multiple burns, cardiopulmonary arrest within the previous 24 h, bone marrow transplant, severe pancreatitis, acute respiratory distress syndrome, and hepatic failure) according to the previous reports by Bates *et al.* (1992). Also collected were other medical condition (malignant diseases, hematological malignant diseases, acute abdomen, central venous line insertion, and use of antibiotics), vital signs [systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), body temperature (BT)], laboratory test results [white blood cell count (WBC), hemoglobin (Hb), platelet cell count (Plt), C-reactive protein (CRP), aspartic aminotransferase (AST), alanine aminotransferase (ALT), blood sugar, serum albumin, total bilirubin, lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine, sodium (Na), potassium (K)], results of blood culture and in-hospital death. These predictor variables were obtained just before the blood culture except for vital signs, which were measured three times a day and all values in the calendar day of blood culture were considered potential predictors. Age brackets were categorized into four groups (<60, 60–69, 70–79, and ≥80 years). Missing data were found in laboratory test results, and the observations without final potential predictors were eliminated from the final analysis. However, patient characteristics and outcomes between patients with and without final predictors, that is, CRP, creatinine, WBC, BUN, LDH, and Hb data were similar ($P = 0.06$–0.9).

Because we would like to make the final prediction rules clear for understanding and easiler for use in clinical practice, continuous variables were dichotomized according to clinical contexts or sample distribution. The cut-off point for the maximum SBP was set at 140 mmHg, for minimum SBP at 90 mmHg, for the maximum DBP at 95 mmHg, and the minimum DBP at 55 mmHg. Maximum/minimum cut-off points were 100/60 beats per min for HR, and 38.5/35.5°C for BT, based on the common practice. The following laboratory test results were dichotomized according to the median of values: WBC with the cut-off point of 10 000 microL^{-1}, Hb with 10.0 g dL^{-1}, Plt with 25 000 microL^{-1}, and CRP with 10.0 mg dL^{-1}. Other laboratory test results were dichotomized by reference values.

Statistical analysis

Univariate correlates for true bacteremia, gram-negative rods, and in-hospital death were determined with chi-square test. These univariate correlates (P-values < 0.10) were then entered into stepwise logistic regression models, which identified the independent predictors for true bacteremia, gram-negative rods, and in-hospital death. Factors with a P-value < 0.05 were retained.

The results of the multivariate analyses were then used to develop clinical prediction models. Beta coefficients of the variables were divided by 0.075 for true bacteremia, 0.5 for gram-negative rods, and 0.11 for in-hospital death, and rounded to the nearest integer (Morimoto *et al.* 2004). The risk scores of an individual patient were determined by assigning points for each factor and totaling these scores. The total risk scores were then stratified into five categories for true bacteremia, four categories for gram-negative rods, and five categories for in-hospital death, according to the level of risk.

The performance of the prediction rule was evaluated by means of receiver operating characteristic (ROC) curve analyses (Metz 1978). The Hosmer-Lemeshow goodness-of-fit statistic was used for calibration (Lemeshow & Hosmer 1982). The jackknife cross validation technique was then applied to the prediction rules to assess their over-fitting (Efron 1982). All statistical analyses were carried out using SAS software (Version 8.02, SAS Institute Inc., Cary, NC).

Results

Patient characteristics

There were 739 blood cultures to analysis during the study period. The patients were 66.0 ± 16.7 (mean ± SD) years old and men accounted for 60.1%. True bacteremia was found in 144 (19.5%) patients and gram-negative rods in 66 (8.9%) (Tables 1 and 2). In-hospital death was recorded for 203 (27.5%) cases including 61 of 144 (42.4%) patients with true bacteremia and 142 of 595 (23.9%) patients without bacteremia, showing a statistically significant difference ($P = 0.001$).

Univariate and multivariate analyses

Univariate correlates for true bacteremia, gram-negative rods, and in-hospital death included age, gender, days from the admission to blood culture, medical condition, vital signs, and laboratory results (Table 3). In-hospital death had a significant correlation with true bacteremia ($P = 0.001$).

Multivariate predictors for true bacteremia comprised age, minimum SBP, maximum BT, minimum BT, days from the admission to blood culture, WBC, CRP, and creatinine. Likewise, multivariate predictors for gram-negative rods included minimum SBP, maximum BT, Plt, CRP, and creatinine, and those for in-hospital death age, major co-morbidity, use of antibiotics, hematological malignant diseases, other malignant diseases, minimum DBP, Hb, LDH, and BUN (Table 4).

Development of the clinical prediction rules

To develop clinical prediction rules, we assigned integer scores proportional to the beta coefficient to the eight identified risk variables for true bacteremia, five for gram-negative rods, and nine for in-hospital death (Table 4). All applicable risk score values were summed to obtain the total risk score for each patient. The rules were then used to categorize the patients into five groups for true bacteremia, four for gram-negative rods, and five for

Table 1 Patient characteristics of blood cultures

	All patients (n = 739) mean ± SD or n (%)
Age, years	66 ± 16.7
Male	444 (60.1)
Days from the admission to blood culture, days	24.2 ± 53.2
Medical conditions	
Major co-morbidity*	153 (20.7)
Malignancy	
Malignancy	132 (17.9)
Hematological malignancy	134 (18.1)
Acute abdomen	69 (9.3)
Medication	
Central venous line insertion	37 (5.0)
On antibiotics	357 (48.3)
Physical examination	
SBP	
Maximum SBP, mmHg	139.5 ± 29.2
Minimum SBP, mmHg	106.5 ± 24.8
DBP	
Maximum DBP, mmHg	78.5 ± 14.7
Minimum DBP, mmHg	58.2 ± 14.8
HR	
Maximum HR, beat min^{-1}	103.9 ± 20.6
Minimum HR, beat min^{-1}	79.5 ± 15.2
BT	
Maximum BT, °C	38.5 ± 1.0
Minimum BT, °C	36.7 ± 0.8
Laboratory results	
WBC, ×100 $microL^{-1}$	104.6 ± 96.8
Hb, g dL^{-1}	10.0 ± 2.5
Plt, ×10 000 $microL^{-1}$	19.2 ± 16.8
CRP, mg dL^{-1}	11.6 ± 9.2
AST, IU L^{-1}	70.6 ± 289.4
ALT, IU L^{-1}	53.7 ± 96.4
Blood Sugar, mg dL^{-1}	153.9 ± 74.2
Albumin, g dL^{-1}	3.0 ± 0.7
Total bilirubin, mg dL^{-1}	1.2 ± 2.0
LDH, IU L^{-1}	456 ± 696.2
BUN, mg dL^{-1}	22.9 ± 18
Creatinine, mg dL^{-1}	1.5 ± 1.6
Na, mEq L^{-1}	136.2 ± 7.4
K, mEq L^{-1}	4.0 ± 0.7
In-hospital death	203 (27.5)
Result of blood culture	
Blood culture positive	243 (32.9)
True positive	144 (19.5)
Gram-negative rods	66 (8.9)
Contamination	99 (13.4)
Blood culture negative	496 (67.1)

SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; BT, body temperature; WBC, white blood cell count; Hb, hemoglobin; Plt, platelet cell count; CRP, C-reactive protein; AST, aspartic aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Na, sodium; K, potassium.

*Major co-morbidity includes coma, brain death, bowel perforation, multiple trauma, multiple burns, cardiopulmonary arrest with in the previous 24 h, bone marrow transplant, severe pancreatitis, acute respiratory distress syndrome, and hepatic failure.

Table 2 Final organism identifications

Organism	*Total* (n = *243*) n (%)	*True bacteremia** (n = *144*) n (%)	*Contamination* (n = *99*) n (%)
Coagulase (–) Staphylococcus	71 (29.2)	6 (4.2)	65 (65.7)
Coagulase (–) Staphylococcus	71 (29.2)	6[†] (4.2)	65 (65.7)
Gram-positive rods	12 (4.9)	1 (0.7)	11 (11.1)
Bacillus sp.	11 (4.5)	1[‡] (0.7)	10 (10.1)
Corynebacterium sp.	1 (0.4)	0 (0.0)	1 (1.0)
Gram-positive cocci	20 (8.2)	14 (9.7)	6 (6.1)
α-hemolytic Streptococcus	3 (1.2)	2[§] (1.4)	1 (1.0)
γ-hemolytic Streptococcus	1 (0.4)	1[¶] (0.7)	0 (0.0)
Enterococcus faecalis	5 (2.1)	3** (2.1)	2 (2.0)
Enterococcus faecium	2 (0.8)	2[††] (1.4)	0 (0.0)
Streptococcus agalactiae	2 (0.8)	1[‡‡] (0.7)	1 (1.0)
Streptococcus constellatus	1 (0.4)	1[§§] (0.7)	0 (0.0)
Streptococcus pneumoniae	3 (1.2)	2[¶¶] (1.4)	1 (1.0)
Streptococcus pyogenes	3 (1.2)	2*** (1.4)	1 (1.0)
Coagulase-positive Staphylococci	50 (20.6)	33 (22.9)	17 (17.2)
Staphylococcus aureus (MSSA)	21 (8.6)	10[†††] (6.9)	11 (11.1)
Staphylococcus aureus (MRSA)	29 (11.9)	23[‡‡‡] (16.0)	6 (6.1)
Gram-negative rods	66 (27.2)	66 (45.8)	0 (0.0)
Acinetobcter calcoaceticus	3 (1.2)	3 (2.1)	0 (0.0)
Aeromonas hydrophila	1 (0.4)	1 (0.7)	0 (0.0)
Burkholderia cepacia	5 (2.1)	5 (3.5)	0 (0.0)
Citrobacter freundii	1 (0.4)	1 (0.7)	0 (0.0)
Citrobacter koseri	1 (0.4)	1 (0.7)	0 (0.0)
Enterobacter aerogenes	3 (1.2)	3 (2.1)	0 (0.0)
Enterobacter cloacae	3 (1.2)	3 (2.1)	0 (0.0)
Escherichia coli	20 (8.2)	20 (13.9)	0 (0.0)
Haemophilus influenzae	1 (0.4)	1 (0.7)	0 (0.0)
Klebsiella oxytoca	1 (0.4)	1 (0.7)	0 (0.0)
Klebsiella pneumoniae	11 (4.5)	11 (7.6)	0 (0.0)
Morganella morganii	2 (0.8)	2 (1.4)	0 (0.0)
Proteus mirabilis	2 (0.8)	2 (1.4)	0 (0.0)
Proteus vulgaris	1 (0.4)	1 (0.7)	0 (0.0)
Pseudomonas aeruginosa	9 (3.7)	9 (6.3)	0 (0.0)
Serratia marcescens	1 (0.4)	1 (0.7)	0 (0.0)
Other gram negative rods	1 (0.4)	1 (0.7)	0 (0.0)
Fungi	17 (7.0)	17 (11.8)	0 (0.0)
Candida albicans	8 (3.3)	8 (5.6)	0 (0.0)
Candida glabrata	7 (2.9)	7 (4.9)	0 (0.0)
Candida sp.	2 (0.8)	2 (1.4)	0 (0.0)
Anaerobic	4 (1.6)	4 (2.8)	0 (0.0)
Bacteroides fragilis	1 (0.4)	1 (0.7)	0 (0.0)
Clostridium perfrigens	2 (0.8)	2 (1.4)	0 (0.0)
Clostridium sp.	1 (0.4)	1 (0.7)	0 (0.0)
Others	3 (1.2)	3[§§§] (2.1)	0 (0.0)

*Positive blood cultures were considered as true bacteremia if the organisms were Gram negative rods, Fungi, or Anaerobic, or if the same organism were cultured more than two times. Two internist's independently reviewed other positive results and classify as positive when both reviewers judge as true positive based on findings; including same organism was detected at the site of infection organ, such as urine, sputa, catheter, operative specimen, and autopsy or patients had endocarditis; [†]more than 2 times: 6; [‡]more than 2 times: 1; [§]infectious endocarditis and operative specimen: 1, same organism was detected at the site of infection organ: 1; [¶]same organism was detected at the site of infection organ: 1; **more than 2 times: 2, same organism was detected at the site of infection organ: 1; [††]more than 2 times: 1, same organism was detected at the site of infection organ: 1; [‡‡]catheter infection: 1; [§§]infectious endocarditis: 1; [¶¶]same organism was detected at the site of infection organ: 2; ***autopsy: 1, same organism was detected at the site of infection organ: 1; [†††]more than 2 times: 5, catheter infection: 2, operative specimen: 1, same organism was detected at the site of infection organ: 2; [‡‡‡]more than 2 times: 8, Autopsy: 1, Catheter infection: 3, Infectious Endocarditis: 1, same organism was detected at the site of infection organ: 10; [§§§]more than 2 times: 2, Autopsy.

Table 3 Univariate correlates of true bacteremia, gram-negative rods, and in-hospital death

Variable	*True bacteremia*			*Gram-negative rods*			*In-hospital death*		
	Yes (n = 144) n (%)	*No (n = 595) n (%)*	P-*Value*	*Yes (n = 66) n (%)*	*No (n = 673) n (%)*	P-*Value*	*Yes (n = 203) n (%)*	*No (n = 536) n (%)*	P-*Value*
Age, years									
<60	25 (17.4)	184 (30.9)	0.005	12 (18.2)	197 (29.3)	0.1	32 (15.8)	177 (33.0)	<0.0001
≥60 and <70	31 (21.5)	124 (20.8)		15 (22.7)	140 (20.8)		36 (17.7)	119 (22.2)	
≥70 and <80	60 (41.7)	176 (29.6)		28 (42.4)	208 (30.9)		84 (41.4)	152 (28.4)	
≥80	28 (19.4)	111 (18.7)		11 (16.7)	128 (19.0)		51 (25.1)	88 (16.4)	
Male	93 (64.5)	351 (59.0)	0.2	42 (63.6)	402 (59.7)	0.5	124 (61.1)	320 (59.7)	0.7
Days from the admission to blood culture ≥14 days	67 (46.5)	219 (36.8)	0.03	25 (37.9)	261 (38.8)	0.9	92 (45.3)	194 (36.2)	0.02
Medical conditions									
Major co-morbidity*	38 (26.4)	115 (19.3)	0.06	16 (24.2)	137 (20.4)	0.5	61 (30.1)	92 (17.2)	0.001
Malignancy									
Malignancy	28 (19.4)	104 (17.5)	0.6	16 (24.2)	116 (17.2)	0.2	49 (24.1)	83 (15.5)	0.006
Hematological malignancy	17 (11.8)	117 (19.7)	0.03	12 (18.2)	122 (18.1)	1.0	45 (22.1)	89 (16.6)	0.08
Acute abdomen	16 (11.1)	53 (8.9)	0.4	9 (13.6)	60 (8.9)	0.2	19 (9.4)	50 (9.3)	1.0
Medication									
Central venous line insertion	12 (8.3)	25 (4.2)	0.04	2 (3.0)	35 (5.2)	1.0	14 (6.9)	23 (4.3)	0.1
On antibiotics	74 (51.4)	283 (47.6)	0.4	30 (45.5)	327 (48.6)	0.6	116 (57.1)	241 (45.0)	0.003

Physical examination									
SBP									
Maximum SBP ≥ 140 mmHg	76 (52.8)	236 (39.7)	0.004	34 (51.5)	278 (41.3)	0.1	100 (49.2)	212 (39.6)	0.02
Minimum SBP ≤ 90 mmHg	54 (37.5)	107 (18.0)	<0.0001	30 (45.5)	131 (19.5)	<0.0001	56 (27.6)	105 (19.6)	0.02
DBP									
Maximum DBP ≥ 95 mmHg	18 (12.5)	67 (11.3)	0.7	8 (12.1)	77 (11.4)	0.9	27 (13.3)	58 (10.8)	0.3
Minimum DBP ≤ 55 mmHg	73 (50.7)	176 (29.6)	<0.0001	40 (60.6)	209 (31.1)	<0.0001	89 (43.8)	160 (29.9)	0.0003
HR									
Maximum HR ≥ 100 min^{-1}	93 (64.6)	264 (44.4)	0.001	43 (65.2)	314 (46.7)	0.004	128 (63.1)	229 (42.7)	<0.0001
Minimum HR ≤ 60 min^{-1}	9 (6.3)	59 (9.9)	0.2	5 (7.6)	63 (9.4)	0.6	14 (6.9)	54 (10.1)	0.2
BT									
Maximum BT ≥ 38.5 °C	89 (61.8)	278 (46.7)	0.001	49 (74.2)	318 (47.3)	0.001	96 (47.3)	271 (50.6)	0.4
Minimum BT ≤ 35.5 °C	12 (8.3)	22 (3.7)	0.02	6 (9.1)	28 (4.2)	0.07	16 (7.9)	18 (3.4)	0.009
Laboratory results									
WBC ≥ 10 000 $microL^{-1}$	77 (53.5)	247 (41.5)	0.009	33 (50.0)	291 (43.2)	0.3	101 (49.8)	223 (41.6)	0.05
Hb ≤ 10.0 g dL^{-1}	90 (62.5)	295 (49.6)	0.005	40 (60.6)	345 (51.3)	0.1	133 (65.5)	252 (47.0)	<0.0001
Plt ≤ 25 000 $microL^{-1}$	16 (11.1)	42 (7.1)	0.1	12 (18.2)	46 (6.8)	0.001	20 (9.9)	38 (7.1)	0.2
CRP ≥ 10.0 mg dL^{-1}	82 (56.9)	238 (40.0)	0.001	40 (60.6)	280 (41.6)	0.003	97 (47.8)	223 (41.6)	0.1
AST ≥ 40 IU L^{-1}	61 (42.4)	165 (27.7)	0.001	21 (31.8)	205 (30.5)	0.8	76 (37.4)	150 (28.0)	0.01
ALT ≥ 35 IU L^{-1}	60 (41.7)	175 (29.4)	0.005	24 (36.4)	211 (31.4)	0.4	69 (14.0)	166 (31.0)	0.4
Blood Sugar ≥126 mg dL^{-1}	81 (56.3)	237 (39.8)	0.001	35 (53.0)	283 (42.1)	0.09	87 (42.9)	231 (43.1)	1.0
Albumin ≤3.5 g dL^{-1}	104 (72.2)	292 (49.1)	<0.0001	49 (74.2)	347 (51.6)	0.0004	122 (60.1)	274 (51.1)	0.03
Total bilirubin ≥1.0 mg dL^{-1}	53 (36.8)	145 (24.4)	0.002	29 (43.9)	169 (25.1)	0.001	60 (29.6)	138 (25.8)	0.3
LDH ≥ 400 IU L^{-1}	34 (23.6)	138 (23.2)	0.9	18 (27.3)	154 (22.9)	0.4	64 (31.5)	108 (20.2)	0.001
BUN ≥ 20.0 mg dL^{-1}	76 (52.8)	179 (30.1)	0.001	34 (51.59)	221 (32.8)	0.002	103 (50.7)	152 (28.4)	0.001
Creatinine ≥1.3 mg dL^{-1}	57 (39.6)	119 (20.0)	0.001	28 (42.4)	148 (22.0)	0.001	69 (34.0)	107 (20.0)	0.001
Na ≥ 145.0 mEq L^{-1}	12 (8.3)	25 (4.2)	0.04	3 (4.6)	34 (5.1)	1.0	18 (8.9)	19 (3.5)	0.003
K ≥ 5.0 mEq L^{-1}	11 (7.6)	33 (5.6)	0.3	3 (4.6)	31 (4.6)	1.0	18 (8.9)	26 (4.9)	0.04

SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; BT, body temperature; WBC, white blood cell count; Hb, hemoglobin; Plt, platelet cell count; CRP, C-reactive protein; AST, aspartic aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Na, sodium; K, potassium.
*Major co-morbidity includes coma, brain death, bowel perforation, multiple trauma, multiple burns, cardiopulmonary arrest with in the previous 24 h, bone marrow transplant, severe pancreatitis, acute respiratory distress syndrome, and hepatic failure.

Table 4 Independent Predictors Identified by Multivariate Analysis

Variable	*Beta*	*Odds ratio*	*95% Confidence interval*	*Points**
True bacteremia				
Intercept	−3.82			
Minimum SBP ≤ 90 mmHg	1.19	3.3	2.0–5.4	16
CRP ≥ 10.0 mg dL^{-1}	0.78	2.2	1.3–3.6	10
Creatinine ≥1.3 mg dL^{-1}	0.75	2.1	1.3–3.4	10
Days from the admission to blood culture ≥14 days	0.82	2.3	1.4–3.7	11
Age ≥ 70 and < 80 years	0.67	2.0	1.2–3.2	9
Maximum BT ≥ 38.5°C	0.93	2.5	1.5–4.2	12
Minimum BT ≤ 35.5°C	0.92	2.5	1.1–5.9	12
WBC ≥ 10 000 $microL^{-1}$	0.45	1.6	1.0–2.5	6
Gram-negative rods				
Intercept	−5.01			
Minimum SBP ≤ 90 mmHg	1.43	4.2	2.2–7.9	3
CRP ≥ 10.0 mg dL^{-1}	1.28	3.6	1.8–7.2	3
Plt ≤ 25 000 $microL^{-1}$	1.53	4.6	1.6–13.1	3
Creatinine ≥1.3 mg dL^{-1}	0.97	2.6	1.4–5.1	2
Maximum BT ≥ 38.5°C	1.44	4.2	2.0–9.0	3
In-hospital death				
Intercept	−4.11			
BUN ≥ 20.0 mg dL^{-1}	1.02	2.8	1.7–4.5	9
LDH ≥ 400 IU L^{-1}	1.01	2.7	1.7–4.4	9
Major co-morbidity†	1.07	2.9	1.7–4.9	10
Hb ≤ 10.0 g dL^{-1}	0.60	1.8	1.1–2.9	6
Age ≥ 60 years	0.89	2.4	1.4–4.4	8
On antibiotics	0.58	1.8	1.1–2.9	5
Hematological malignancy	0.98	2.7	1.5–4.8	9
Malignancy	1.03	2.8	1.5–5.1	9
Minimum DBP ≤ 55 mmHg	0.65	1.9	1.2–3.1	6

The risk score for an individual patient was determined each true bacteremia, gram-negative rods, and in-hospital death by assigning points for each factor present and summing. The resulting risk score was then used in Table 4 to estimate the each probability of true bacteremia, gram-negative rods, and in-hospital death.

SBP, systolic blood pressure; CRP, C-reactive protein; BT, body temperature; WBC, white blood cell count; Plt, platelet cell count; BUN, blood urea nitrogen; LDH, lactate dehydrogenase; Hb, hemoglobin; DBP, diastolic blood pressure.

*Calculated by diving the β coefficient by 0.075 (True bacteremia), 0.5 (Gram-negative rods), and 0.11 (In-hospital death) and rounding to the nearest integer.

†major co-morbidity includes coma, brain death, bowel perforation, multiple trauma, multiple burns, cardiopulmonary arrest with in the previous 24 h, bone marrow transplant, severe pancreatitis, acute respiratory distress syndrome and hepatic failure.

in-hospital death with varying likelihood of each outcome (Fig. 1).

The subject patients were divided into the following 5 groups according to the risk probability of bacteremia: (1) patients with 7% risk (very-low-risk group, score: 0–14); (2) those with 10% risk (low-risk group, risk score: 15–25); (3) those with 22% risk (average-risk group, risk score: 26–35); (4) those with 30% risk (intermediate-risk group, risk score: 36–48); and (5) those with 60% risk (high-risk group, score ≥ 49) (Fig. 1).

Similarly, risks of blood culture positive for gram-negative rods were predicted from 1% (very-low-risk group, risk score: 0–2) to 32% (high-risk group, risk score ≥ 8) and those of in-hospital death were estimated from 7% (very-low-risk group, risk score: 0–13) to 56% (high-risk group, risk score ≥ 34) (Fig. 1).



Figure 1 Performance of the prediction rules. a, true bacteremia; b, gram-negative rods; c, in-hospital death.

Calibration

The rules we came up with here performed well with ROC curve analyses in predicting true bacteremia, blood culture positive for gram-negative rods, and in-hospital death. The respective areas under the curve were 0.73 ± 0.02 (mean ± SE), 0.64 ± 0.02, and 0.64 ± 0.02 respectively (Fig. 2). Calibrations of the three models were tested on the entire cohort and proved satisfactory (Fig. 3). Hosmer-Lemeshow goodness-of-fit test *P*-values were 0.6, 1.0, and 0.07 for true bacteremia, blood culture positive for gram-negative rods, and in-hospital death respectively.



Figure 2 Receiver operating characteristic curves for true bacteremia (a), gram-negative rods (b), and in-hospital death (c). The area under the curves are 0.73 ± 0.02 (a), 0.64 ± 0.02 (b), and 0.64 ± 0.02 (c) and for the original cohort. The straight, diagonal broken lines represent the tests without discriminative ability. AUC, area under the receiver operating characteristic curve ± standard error.